Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study

Schizophrenia Research

Volumn 161, Issue 2-3, 2015, Pages 252-260

  Hugdahl, Kenneth ^a,b,c   Craven, Alexander R ^a   Nygård, Merethe ^a   Løberg, Else Marie ^a,b   Berle, Jan Øystein ^b   Johnsen, Erik ^a,b   Kroken, Rune ^b   Specht, Karsten ^a,b   Andreassen, Ole A ^c   Ersland, Lars ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Auditory hallucinations; Glutamate; MR; MR spectroscopy; Schizophrenia

Indexed keywords

GLUTAMIC ACID; PROTON;

ADULT; AMINO ACID BRAIN LEVEL; ARTICLE; AUDITORY HALLUCINATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMOTIONAL WITHDRAWAL; FEMALE; FRONTAL LOBE; HUMAN; MALE; NEGATIVE SYNDROME; NEUROCHEMISTRY; NEUROIMAGING; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TEMPORAL LOBE; VOXEL BASED MORPHOMETRY; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; COMPLICATION; HALLUCINATIONS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PSYCHOLOGICAL RATING SCALE;

ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; FEMALE; GLUTAMIC ACID; HALLUCINATIONS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 84921605046     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.11.015     Document Type: Article

References (58)

1. Aleman A., Vercammen A. Functional neuroimaging in schizophrenia. Hallucinations - Research and Practice 2012, 267-282. Springer Verlag, New York, NY. J.D. Blom, I.E.C. Sommer (Eds.).
2. Allen P., Modinos G. Structural neuroimaging in psychotic patients with auditory hallucinations. Hallucinations - Research and Practice 2012, 251-266. Springer Verlag, New York. J.D. Blom, I.E.C. Sommer (Eds.).
3. Allen P., Modinos G., Hubl D., Shields G., Cachia A., Jardri R., Thomas P., Woodward T., Shotbolt P., Plaze M., Hoffman R. Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neurochemistry and beyond. Schizophr. Bull. 2012, 38:695-703.
4. Bentaleb L.A., Beauregard M., Liddle P., Stip E. Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J. Psychiatry Neurosci. 2002, 27:110-115.
5. Brandao L., Domingues R.C. MR Spectroscopy of the Brain 2004, Lippincott Publishers, Philadelphia, PA.
6. Carlsson A., Waters N., Holm-Waters S.Tedroff, Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 2001, 41:237-260.
7. Coyle J.T., Basu A., Benneyworth M., Balu D., Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handbook of Experimental Pharmacology 213 2012, 268-295. Springer Verlag, Berlin-Heidelberg. M.A. Geyer, G. Gross (Eds.).
8. David A.S. Auditory hallucinations: phenomenology, neuropsychology, and neuroimaging update. Acta Psychiatr. Scand. 1999, 395:95-104.
9. Davis J.M. Dose equivalence of the antipsychotic drugs. J. Psychiatr. Res. 1974, 11:65-69.
10. de la Fuente-Sandoval C., Leon-Ortiz P., Favila R., Stephano S., Mamo D., Ramírez-Bermudez J., Graff-Guerrero A. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
11. 1H-MRS imaging study. Int. J. Neuropsychopharmacol. 2013, 16:471-475.
12. de la Fuente-Sandoval C., Leon-Ortiz P., Azcarraga M., Stephano S., Favila R., Diaz-Galvis L., Alvarado-Alanis P., Ramirez-Bermudez J., Graff-Guerrero A. Glutamate levels in the associative striatum before and after 4weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013, 70:1057-1066.
13. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry 2014, 75:e11-e13.
14. Falkenberg L.E., Westerhausen R., Specht K., Hugdahl K. Resting-state glutamate level in the anterior cingulate predicts blood-oxygen level-dependent response to cognitive control. Proc. Natl. Acad. Sci. 2012, 109:5069-5073.
15. Ford J.M., Mathalon D.H., Kalba S., Whitfield S., Faustman W.O., Roth W.T. Cortical responsiveness during talking and listening in schizophrenia: an event-related brain potential study. Biol. Psychiatry 2001, 50:540-549.
16. Ford J.M., Mathalon D.H., Whitfield S., Faustman W.O., Roth W.T. Reduced communication between frontal and temporal lobes during talking in schizophrenia. Biol. Psychiatry 2002, 51:485-492.
17. Ford J.M., Dierks T., Fisher D.J., Herrmann C.S., Hubl D., Kindler M., Koenig T., Mathalon D.H., Spencer K.M., Strik W., van Lutterveld R. Neurophysiological studies of auditory verbal hallucinations. Schizophr. Bull. 2012, 38:715-723.
18. Gaser C., Nenadic I., Volz H.-P., Büchel C., Sauer H. Neuroanatomy of 'hearing voices': a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb. Cortex 2004, 14:91-96.
19. Green M.F., Hugdahl K., Mitchell S. Dichotic listening during auditory hallucinations in schizophrenia. Am. J. Psychiatr. 1994, 151:357-362.
20. Green M.F., Kern R.S., Braff D.-L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring "the right stuff"?. Schizophr. Bull. 2000, 26:119-136.
21. Haraldsson H.M., Ferrarelli F., Kalin N.H., Tononi G. Transcranial magnetic stimulation in the investigation and treatment of schizophrenia: a review. Schizophr. Res. 2004, 71:1-16.
22. Homan P., Vermathen P., Van Swam P., Federspie A., Boesch C., Strik W., Dierks T., Hubl D., Kreis R. Magnetic resonance spectroscopy investigations of functionally defined language areas in schizophrenia patients with and without auditory hallucinations. Neuroimage 2014, 94:23-32.
23. Hugdahl K., Løberg E.-M., Falkenberg L.E., Johnsen E., Kompus K., Kroken R., Nygård M., Westerhausen R., Altekin K., Özgören M. Auditory verbal hallucinations in schizophrenia as aberrant lateralized speech perception: evidence from dichotic listening. Schizophr. Res. 2012, 140:59-64.
24. Jardri R., Pouchet A., Pins D., Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am. J. Psychiatr. 2010, 168:73-81.
25. Johnsen E., Hugdahl K., Fusar-Poli P., Kroken R., Kompus K. Neuropsychopharmacology of auditory hallucinations: insights from pharmacological MRI and perspectives for future research. Expert. Rev. Neurother. 2013, 13:23-36.
26. Kapur S., Wadenberg M.L., Remington G. Are animal models of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can. J. Psychiatr. 2000, 45:241-246.
27. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
28. Kegeles L.S., Mao X., Stanford A.D., Girgis R., Ojeil N., Xu X., Gil R., Slifstein M., Abi-Dargham A., Lisanby S.H., Shungu D.C. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 2012, 69:449-459.
29. Kompus K., Westerhausen R., Hugdahl K. The "paradoxical" engagement of the primary auditory cortex in patients with auditory verbal hallucinations: a meta-analysis of functional neuroimaging studies. Neuropsychologia 2011, 49:3361-3369.
30. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
31. Lewis D.A. The chandelier neuron in schizophrenia. Dev. Neurobiol. 2011, 71:118-127.
32. Lewis D.A., Sweet R.A. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Investig. 2009, 119:706-716.
33. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Neurosci. Rev. 2005, 6:312-324.
34. Løberg E.M., Hugdahl K., Green M.F. Hemispheric asymmetry in schizophrenia: a "dual deficits" model. Biol. Psychiatry 1999, 45:76-81.
35. Løberg E.-M., Nygård M., Berle J., Kroken R., Jørgensen H., Hugdahl K. An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Hum. Neurosci. 2012, 3. 10.3389/fpsyt.2012.00094.
36. 1H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
37. Martinez-Granados B., Brotons O., Martinez-Bisbal M.C., Celda B., Marti-Bonmati L., Aguilar E.J., Sanjuan J. Spectroscopic metabolic abnormalities in the thalamus related to auditory hallucinations in patients with schizophrenia. Schizophr. Res. 2008, 104:13-22.
38. McGuire P.K., Silbersweig D.A., Wright I., Murray R.M., David A.S., Frackowiak R.S.J., Frith C.D. Abnormal monitoring of inner speech: a physiological basis for auditory hallucinations. Lancet 1995, 346:596-600.
39. McGuire P.K., Silbersweig D.A., Wright I., Murray R.M., Frackowiak R.S., Frith C.D. The neural correlates of inner speech and auditory verbal imagery in schizophrenia: relationship to auditory verbal hallucinations. Br. J. Psychiatry 1996, 169:148-159.
40. Modinos G., Costafreda S.G., van Tol M.-J., McGuire P.K., Aleman A., Allen P. Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies. Cortex 2013, 49:1046-1055.
41. Neckelmann G., Specht K., Lund A., Ersland L., Smievoll A.I., Neckelmann D., Hugdahl K. MR morphometry analysis of grey matter volume reduction in schizophrenia: association with hallucinations. Int. J. Neurosci. 2006, 116:9-23.
42. Nenadic I., Dietzek M., Langbein K., Rzanny R., Gussew A., Reichenbach J.R., Sauer H., Smesny S. Superior temporal metabolic changes related to auditory hallucinations: a 31P-MR spectroscopy study in antipsychotic-free schizophrenia patients. Brain Struct. Funct. 2013, 219:1689-1672.
43. Nygård M., Eichele T., Løberg E.-M., Jørgensen H., Johnsen E., Kroken R., Berle Ø., Hugdahl K. Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 2012, (103389.fnhum.2012.00149).
44. Nygård M., Løberg E.-M., Craven A., Ersland L., Berle J.Ø., Kroken R., Johnsen E., Hugdahl K. Dichotic listening, executive functions and grey matter cortical volume in patients with schizophrenia and healthy controls. Scand. J. Psychol. 2013, 54:443-450.
45. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
46. Poels E.M.P., Kegeles L.S., Kantrowitz J.T., Slifstein M., Javitt D.-C., Lieberman J.A., Abi-Dargham A., Girgis R.R. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol. Psychiatry 2014, 19:20-29.
47. Puts N.A.J., edden R.A.E. In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog. Nucl. Magn. Reson. Spectrosc. 2012, 60:29-41.
48. Ronning M. The WHO Collaborating Centre for Drug Statistics Methodology 1982, Established, (http://www.whocc.no/atcddd. Accessed August 3. 2014).
49. Rund N.R., Sundet K., Asbjørnsen A., Egeland J., Landrø N.I., Lund A., Roness A., Stordal K.I., Hugdahl K. Neuropsychological test-profiles in schizophrenia and non-psychotic depression. Acta Psychiatr. Scand. 2006, 113:350-359.
50. Sanjuan J., Aguilar E.J., Artigas F. Pharmacological treatment of hallucinations. Hallucinations - A Guide to Treatment and Management 2010, 9-28. Oxford University Press, New York, NY. F. Larøi, A. Aleman (Eds.).
51. Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., Jones T., Frackowiak R.J.S. A functional neuroanatomy study of hallucinations in schizophrenia. Nature 1995, 378:176-179.
52. Magnetic Resonance Spectroscopy - Tools for Neuroscience Research and Emerging Clinical Applications 2014, Academic Press, London, UK. C.J. Stagg, D.L. Rothman (Eds.).
53. Taylor M. MRS of psychiatric disorders. Magnetic Resonance Spectroscopy - Tools for Neuroscience Research and Emerging Clinical Applications 2014, 222-228. Academic Press, London, UK, (2014). C.J. Stagg, D.L. Rothman (Eds.).
54. van Tol M.J., van der Meer L., Bruggeman R., Modinos G., Knegtering H., Aleman A. Voxel-based gray and white matter morphometry correlates of hallucinations in schizophrenia: the superior temporal gyrus does not stand alone. Neuroimage Clin. 2013, 4:249-257.
55. Wageningen H., Jørgensen H., Specht K., Hugdahl K. Evidence for glutamatergic neurotransmission in cognitive control in an auditory attention task. Neurosci. Lett. 2009, 454:171-175.
56. Wageningen H., Jørgensen H., Specht K., Hugdahl K. A H-1-MR spectroscopy study of changes in glutamate and glutamine (Glx) levels in frontal spectra after administration of memantine. Cereb. Cortex 2010, 20:798-803.
57. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137:246-250.
58. Westerhausen R., Moosmann M., Alho K., Belsby S.O., Hämäläinen H., Medvedev S., Specht K., Hugdahl K. Identification of attention and cognitive control networks in a parametric auditory fMRI study. Neuropsychologia 2010, 48:2075-2081.